Table 3.
Clinical relapses in patients from General University Hospital in Prague.1
| NO. OF PATIENTS WITH AT LEAST 1 CLINICAL RELAPSE (ALL) | p value | |
|---|---|---|
| In 90 days after vaccination | 88 (5.30%)2 | |
| Time between 1st dose of vaccine and relapse (SD), d | 41.08 (26.80) | |
| Between 0–90 days before vaccination | 63 (3.79%)3 | 0.043 |
| Between 90–180 days before vaccination | 64 (3.85%)4 | 0.039 |
| Between 180–270 days before vaccination | 71 (4.27%)5 | 0.181 |
| Between 360–270 days before vaccination | 74 (4.46%)6 | 0.279 |
| In 90 days after COVID-19 | 36 (7.27%)7 | |
| Time between COVID-19 onset and relapse (SD), d | 38.17 (25.10) | |
| Between 0–90 days before COVID-19 | 34 (6.87%)8 | 0.896 |
| Between 90–180 days before COVID-19 | 23 (4.65%)9 | 0.080 |
| Between 180–270 days before COVID-19 | 25 (5.05%)10 | 0.185 |
| Between 270–360 days before COVID-19 | 22 (4.44%)11 | 0.077 |
| Annualised relapse rate after vaccination | 0.22 | 0.036 |
| Annualised relapse rate before vaccination | 0.17 | |
| Annualised relapse rate after COVID-19 | 0.29 | 0.129 |
| Annualised relapse rate before COVID-19 | 0.22 | |
| NO. OF PATIENTS WITH AT LEAST 1 CLINICAL RELAPSE (PATIENTS WITH DMT CHANGES EXCLUDED) | ||
| In 90 days after vaccination | 79 (4.90%) | 0.020 |
| Between 0 - 90 days before vaccination | 52 (3.22%) | |
| In 90 days after vaccination | 75 (4.80%) | <0.001 |
| Between 90 - 180 days before vaccination | 38 (2.43%) | |
| In 90 days after vaccination | 71 (4.67%) | 0.003 |
| Between 180 - 270 days before vaccination | 39 (2.57%) | |
| In 90 days after vaccination | 64 (4.36%) | <0.001 |
| Between 270 - 360 days before vaccination | 23 (1.57%) | |
| In 90 days after COVID-19 | 32 (6.88%) | 0.665 |
| Between 0 - 90 days before COVID-19 | 28 (6.02%) | |
| In 90 days after COVID-19 | 30 (6.67%) | 0.006 |
| Between 90 - 180 days before COVID-19 | 12 (2.67%) | |
| In 90 days after COVID-19 | 28 (6.39%) | 0.025 |
| Between 180 - 270 days before COVID-19 | 13 (2.97%) | |
| In 90 days after COVID-19 | 27 (6.46%) | 0.003 |
| Between 270 - 360 days before COVID-19 | 9 (2.15%) | |
| Annualised relapse rate after vaccination | 0.18 | <0.001 |
| Annualised relapse rate before vaccination | 0.09 | |
| Annualised relapse rate after COVID-19 | 0.26 | 0.009 |
| Annualised relapse rate before COVID-19 | 0.13 | |
DMT = disease modifying therapy; 1. 1661 patients with MS from General University Hospital in Prague were vaccinated, 495 experienced COVID-19; 2. 3 patients had 2 relapses, 29 (31.87%) relapses were mild, 56 (61.54%) moderate and 6 (6.59%) severe; 3. 1 patient had 2 relapses, 30 (46.88%) relapses were mild, 28 (43.75%) moderate and 6 (9.38%) severe; 4. 1 patient had 2 relapses, 16 (24.62%) relapses were mild, 47 (72.31%) moderate and 2 (3.08%) severe; 5. 3 patients had 2 relapses, 28 (37.84%) relapses were mild, 44 (59.46%) moderate and 2 (2.70%) severe; 6. 2 patients had 2 relapses, 25 (32.89%) relapses were mild, 46 (60.53%) moderate and 5 (6.58%) severe; 7. relapse was mild in 16 (44.44%), moderate in 18 (50.00%) and severe in 2 (5.56%) patients; 8. 1 patient had 2 relapses, 14 (40.00%) relapses were mild, 21 (60.00%) moderate and 0 severe; 9. relapse was mild in 6 (26.09%), moderate in 15 (65.22%) and severe in 2 (8.70%) patients; 10. 1 patient had 2 relapses, 13 (50.00%) relapses were mild, 12 (46.15%) moderate and 1 (3.85%) severe; 11. 1 patient had 2 relapses, 9 (39.13%) relapses were mild, 11 (47.83%) moderate and 3 (13.04%) severe.